190 related articles for article (PubMed ID: 8123853)
21. The prognostic significance of chromosomal analysis and immunophenotyping in 117 patients with de novo acute myeloid leukemia.
de Nully Brown P; Jurlander J; Pedersen-Bjergaard J; Victor MA; Geisler CH
Leuk Res; 1997 Oct; 21(10):985-95. PubMed ID: 9403009
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
[TBL] [Abstract][Full Text] [Related]
23. Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosis.
Amadori S; Venditti A; Del Poeta G; Stasi R; Buccisano F; Bruno A; Tamburini A; Cox MC; Maffei L; Aronica G; Simone MD; Adorno G; Masi M; Tribalto M; Papa G
Ann Hematol; 1996 Apr; 72(4):208-15. PubMed ID: 8624374
[TBL] [Abstract][Full Text] [Related]
24. Acute myeloblastic leukemia with minimal myeloid differentiation (FAB AML-M0): a study of eleven cases.
Sempere A; Jarque I; Guinot M; Palau J; García R; Sanz GF; Gomis F; Pérez-Sirvent ML; Senent L; Sanz MA
Leuk Lymphoma; 1993 Dec; 12(1-2):103-8. PubMed ID: 8161925
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience.
Plesa C; Chelghoum Y; Plesa A; Elhamri M; Tigaud I; Michallet M; Dumontet C; Thomas X
Cancer; 2008 Feb; 112(3):572-80. PubMed ID: 18085638
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic significance of CD7 expression in adult acute myeloid leukemia].
Saito T; Usui N; Dobashi N; Maki N; Asai O; Yano S; Kato A; Watanabe H; Katori M; Nagamine M; Ogihara A; Yamazaki H; Kobayashi T; Tajima N; Kuraishi Y
Rinsho Ketsueki; 1998 Jul; 39(7):481-6. PubMed ID: 9750454
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
Chang H; Salma F; Yi QL; Patterson B; Brien B; Minden MD
Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079
[TBL] [Abstract][Full Text] [Related]
28. Chromosome aberrations in CD34-positive acute myeloid leukemia. Correlation with clinicopathologic features.
Fagioli F; Cuneo A; Carli MG; Bardi A; Piva N; Previati R; Rigolin GM; Ferrari L; Spanedda R; Castoldi G
Cancer Genet Cytogenet; 1993 Dec; 71(2):119-24. PubMed ID: 7506635
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of patients with de novo acute myeloid leukaemia and isolated trisomy 11: a Cancer and Leukemia Group B study.
Heinonen K; Mrózek K; Lawrence D; Arthur DC; Pettenati MJ; Stamberg J; Qumsiyeh MB; Verma RS; MacCallum J; Schiffer CA; Bloomfield CD
Br J Haematol; 1998 Jun; 101(3):513-20. PubMed ID: 9633896
[TBL] [Abstract][Full Text] [Related]
30. The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38- leukemic progenitors.
Costello R; Mallet F; Chambost H; Sainty D; Arnoulet C; Gastaut JA; Olive D
Leukemia; 1999 Oct; 13(10):1513-8. PubMed ID: 10516751
[TBL] [Abstract][Full Text] [Related]
31. [Immunocytochemistry in the diagnosis of acute myeloid leukemia (M0)].
Saito M; Kuriyama K; Nagai K; Nonaka H; Hata T; Tusima H; Tabata S; Arimura K; Souda H; Nakamura H
Rinsho Ketsueki; 1994 Nov; 35(11):1297-304. PubMed ID: 7823396
[TBL] [Abstract][Full Text] [Related]
32. Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities.
Kern W; Schoch C; Haferlach T; Braess J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
Leukemia; 2000 Feb; 14(2):226-31. PubMed ID: 10673737
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
List AF; Spier CS; Grogan TM; Johnson C; Roe DJ; Greer JP; Wolff SN; Broxterman HJ; Scheffer GL; Scheper RJ; Dalton WS
Blood; 1996 Mar; 87(6):2464-9. PubMed ID: 8630412
[TBL] [Abstract][Full Text] [Related]
34. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.
Schnittger S; Kinkelin U; Schoch C; Heinecke A; Haase D; Haferlach T; Büchner T; Wörmann B; Hiddemann W; Griesinger F
Leukemia; 2000 May; 14(5):796-804. PubMed ID: 10803509
[TBL] [Abstract][Full Text] [Related]
35. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
[TBL] [Abstract][Full Text] [Related]
36. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
37. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
[TBL] [Abstract][Full Text] [Related]
38. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma.
Kita K; Miwa H; Nakase K; Kawakami K; Kobayashi T; Shirakawa S; Tanaka I; Ohta C; Tsutani H; Oguma S
Blood; 1993 May; 81(9):2399-405. PubMed ID: 7683218
[TBL] [Abstract][Full Text] [Related]
39. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
Muñoz L; Nomdedéu JF; Villamor N; Guardia R; Colomer D; Ribera JM; Torres JP; Berlanga JJ; Fernández C; Llorente A; Queipo de Llano MP; Sánchez JM; Brunet S; Sierra J;
Leukemia; 2003 Jan; 17(1):76-82. PubMed ID: 12529663
[TBL] [Abstract][Full Text] [Related]
40. Multivariate analysis of factors associated with outcome of treatment for adults with acute myelogenous leukemia.
Schwartz RS; Mackintosh FR; Halpern J; Schrier SL; Greenberg PL
Cancer; 1984 Oct; 54(8):1672-81. PubMed ID: 6592033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
